Table 2.
Treatment characteristics (n = 42)
| Number of patients | Prostate (n = 33) | Prostate bed (n = 9) | Total (n = 42) |
| Pre reirradiation PSA | |||
| Median [range] (months) | 3.3 [0.05;23.7] | 1.1 [0.01;3.1] | 3.1 [0.01;23.7] |
| ADT group | 0,4 [0.05–1.1] | 0,3 [0.01–0.07] | 0,3 [0.01–1.1] |
| Non-ADT group | 4 [2.5–23.7] | 2.6 [2.2–3.1] | 3,9 [2.2–23.7] |
| ADT added to reirradiation | 5 | 3 | 8 (19%) |
| Median duration of ADT (months) | 6 | 6.1 | 6 |
| Median time from start of ADT to re irradiation (months) | 3 [1-10] | 3 [1-5] | 3 [1-10] |
| Recurrence biopsy proven | 28 | 6 | 34 (80%) |
| Pelvic MRI before reirradiation | 33 (78%) | 9 (22%) | 42 (100%) |
| Rectal spacers | 23 | 0 | 23 (55%) |
| CyberKnife ® data | |||
| Median total dose (Gy) | 36 | 36 | 36 |
| Dose/fraction | 6 | 6 | 6 |
| Number of fractions | 6 | 6 | 6 |
| Estimated duration of a fraction (mn) | 30.7 | 28.8 | 30.3 |